Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab with anti-LAG-3 and anti-TIM-3 in first-line PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
2023-504270-38-00Phase 2Completed
- Sponsor
- Incyte
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of retifanlimab, tuparstobart and verzistobart in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Incyte. Primary endpoint: Progression-free survival. Started Oct 2024; status: completed.
02
Drugs
retifanlimabtuparstobartverzistobart
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-504270-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504270-38-00.